Open AccessPembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE ‐024 trial
Author(s) -
Li Fengtan,
Dong Xifeng
Publication year - 2021
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.14193
Subject(s) - medicine , pembrolizumab , oncology , term (time) , lung cancer , cancer , intensive care medicine , immunotherapy , physics , quantum mechanics